Use of Tricyclo-DNA Antisense Oligonucleotides for Exon Skipping View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2018-09-01

AUTHORS

Karima Relizani , Aurelie Goyenvalle

ABSTRACT

Antisense oligonucleotides (AONs) have been actively developed for more than 30 years as a form of molecular medicine and represent promising therapeutic tools for many disorders. Significant progress has been made toward their clinical development in particular for splice switching AONs for the treatment of neuromuscular disorders such as Duchenne muscular dystrophy (DMD). Many different chemistries of AONs can be used for splice switching modulation, and some of them have now reached regulatory approval. However, despite advances in AON chemistry and design, systemic use of AONs is limited due to poor tissue uptake and sufficient therapeutic efficacy is difficult to achieve. Therefore, there is still a critical need to develop efficient AONs able to target all relevant tissues and international efforts are currently on going to advance new compounds or alternative chemistries with higher therapeutic potential. Here we describe the methods to evaluate the potency of tricyclo-DNA (tcDNA)-AONs, a novel class of AONs which displays unique pharmacological properties and unprecedented uptake in many tissues after systemic administration (Goyenvalle et al., Nat Med 21:270-275, 2015; Goyenvalle et al., J Neuromuscul Dis 3:157-167, 2016; Relizani et al., Mol Ther Nucleic Acids 8:144-157, 2017; Robin et al., Mol Ther Nucleic Acids 7:81-89, 2017). We will focus on the preclinical evaluation of these tcDNA for DMD, specifically targeting the exon 51 of the human dystrophin gene. We will first detail methods to analyze their efficacy both in vitro in human myoblasts and in vivo in the hDMD and mdx52 mouse models and then describe means to evaluate their potential renal toxicity. More... »

PAGES

381-394

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-4939-8651-4_24

DOI

http://dx.doi.org/10.1007/978-1-4939-8651-4_24

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1106471691

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30171555


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1004", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical Biotechnology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/10", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Technology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cells, Cultured", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dystrophin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Exons", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gene Targeting", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Muscular Dystrophy, Duchenne", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myoblasts", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oligodeoxyribonucleotides, Antisense", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "RNA Splicing", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transfection", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Versailles Saint-Quentin-en-Yvelines University", 
          "id": "https://www.grid.ac/institutes/grid.12832.3a", 
          "name": [
            "Universit\u00e9 de Versailles St-Quentin, U1179 INSERM, UFR des Sciences de la Sant\u00e9\u2014LIA BAHN CSM, Versailles, France", 
            "SQY Therapeutics, UFR des Sciences de la Sant\u00e9, Montigny-le-Bretonneux, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Relizani", 
        "givenName": "Karima", 
        "id": "sg:person.01026571624.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026571624.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Versailles Saint-Quentin-en-Yvelines University", 
          "id": "https://www.grid.ac/institutes/grid.12832.3a", 
          "name": [
            "Universit\u00e9 de Versailles St-Quentin, U1179 INSERM, UFR des Sciences de la Sant\u00e9\u2014LIA BAHN CSM, Versailles, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goyenvalle", 
        "givenName": "Aurelie", 
        "id": "sg:person.01200571036.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200571036.55"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.coph.2015.07.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002005310"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/nar/gkp841", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005271115"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3233/jnd-160146", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013977294"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.3765", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014266352", 
          "https://doi.org/10.1038/nm.3765"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/nat.2016.0657", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021448721"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1038/mt.2016.188", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024312237"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1006/bbrc.1997.7328", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026152845"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/nar/29.9.e45", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030834024"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1038/mtna.2014.6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031003220"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ymthe.2004.05.031", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045117278"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1474-4422(16)30035-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049531945"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/2044-5040-1-34", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051788803", 
          "https://doi.org/10.1186/2044-5040-1-34"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.omtn.2017.02.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084100080"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.15252/emmm.201607199", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084343659"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.omtn.2017.06.013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1086143160"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.omtn.2017.06.013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1086143160"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-09-01", 
    "datePublishedReg": "2018-09-01", 
    "description": "Antisense oligonucleotides (AONs) have been actively developed for more than 30\u00a0years as a form of molecular medicine and represent promising therapeutic tools for many disorders. Significant progress has been made toward their clinical development in particular for splice switching AONs for the treatment of neuromuscular disorders such as Duchenne muscular dystrophy (DMD). Many different chemistries of AONs can be used for splice switching modulation, and some of them have now reached regulatory approval. However, despite advances in AON chemistry and design, systemic use of AONs is limited due to poor tissue uptake and sufficient therapeutic efficacy is difficult to achieve. Therefore, there is still a critical need to develop efficient AONs able to target all relevant tissues and international efforts are currently on going to advance new compounds or alternative chemistries with higher therapeutic potential. Here we describe the methods to evaluate the potency of tricyclo-DNA (tcDNA)-AONs, a novel class of AONs which displays unique pharmacological properties and unprecedented uptake in many tissues after systemic administration (Goyenvalle et al., Nat Med 21:270-275, 2015; Goyenvalle et al., J Neuromuscul Dis 3:157-167, 2016; Relizani et al., Mol Ther Nucleic Acids 8:144-157, 2017; Robin et al., Mol Ther Nucleic Acids 7:81-89, 2017). We will focus on the preclinical evaluation of these tcDNA for DMD, specifically targeting the exon 51 of the human dystrophin gene. We will first detail methods to analyze their efficacy both in vitro in human myoblasts and in vivo in the hDMD and mdx52 mouse models and then describe means to evaluate their potential renal toxicity.", 
    "editor": [
      {
        "familyName": "Yokota", 
        "givenName": "Toshifumi", 
        "type": "Person"
      }, 
      {
        "familyName": "Maruyama", 
        "givenName": "Rika", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-4939-8651-4_24", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-4939-8650-7", 
        "978-1-4939-8651-4"
      ], 
      "name": "Exon Skipping and Inclusion Therapies", 
      "type": "Book"
    }, 
    "name": "Use of Tricyclo-DNA Antisense Oligonucleotides for Exon Skipping", 
    "pagination": "381-394", 
    "productId": [
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30171555"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1106471691"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-4939-8651-4_24"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "bc47a79cde86a71777469b21829288ea7894938edce0caec2c7f0d8254b01c21"
        ]
      }
    ], 
    "publisher": {
      "location": "New York, NY", 
      "name": "Springer New York", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-4939-8651-4_24", 
      "https://app.dimensions.ai/details/publication/pub.1106471691"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2019-04-16T09:14", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000371_0000000371/records_130805_00000006.jsonl", 
    "type": "Chapter", 
    "url": "https://link.springer.com/10.1007%2F978-1-4939-8651-4_24"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-4939-8651-4_24'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-4939-8651-4_24'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-4939-8651-4_24'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-4939-8651-4_24'


 

This table displays all metadata directly associated to this object as RDF triples.

189 TRIPLES      23 PREDICATES      57 URIs      35 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-4939-8651-4_24 schema:about N0f365b4fa29242a692d4f6cde6726eaf
2 N1e82d14b499f4d939188e64d228f4cdd
3 N626c9a2c092c40f3951c9eb72f52fed8
4 N68194a9edeff4940858ebb0d286599bb
5 N6c6438a5ac124a828b5cc7b679f000ae
6 N74d78c908cfc45d18d5ee7eac51b3cc9
7 N74fdc178f3e5483a8d088767cf6f27df
8 N766a599cef2a4b60b3ffa21a74b2bcf6
9 Na3e19250e721494eabbba247b3dac7ec
10 Nacd67dd374c443d89a459a19777e0584
11 Naeecbf79d898490db9f1e1b70066736c
12 Nb0875e27a77d475f899f1f3c7ac6cbae
13 Nbcd3aae98702418da9c43cfe80395b7a
14 Nd88676cd27f14e6eafc9cbb8f0eb8e1f
15 Ndd1a6a0b4a224b538893e9093d19fd6e
16 anzsrc-for:10
17 anzsrc-for:1004
18 schema:author N4768b22eabc0470b914dcec3487b1491
19 schema:citation sg:pub.10.1038/nm.3765
20 sg:pub.10.1186/2044-5040-1-34
21 https://doi.org/10.1006/bbrc.1997.7328
22 https://doi.org/10.1016/j.coph.2015.07.005
23 https://doi.org/10.1016/j.omtn.2017.02.009
24 https://doi.org/10.1016/j.omtn.2017.06.013
25 https://doi.org/10.1016/j.ymthe.2004.05.031
26 https://doi.org/10.1016/s1474-4422(16)30035-7
27 https://doi.org/10.1038/mt.2016.188
28 https://doi.org/10.1038/mtna.2014.6
29 https://doi.org/10.1089/nat.2016.0657
30 https://doi.org/10.1093/nar/29.9.e45
31 https://doi.org/10.1093/nar/gkp841
32 https://doi.org/10.15252/emmm.201607199
33 https://doi.org/10.3233/jnd-160146
34 schema:datePublished 2018-09-01
35 schema:datePublishedReg 2018-09-01
36 schema:description Antisense oligonucleotides (AONs) have been actively developed for more than 30 years as a form of molecular medicine and represent promising therapeutic tools for many disorders. Significant progress has been made toward their clinical development in particular for splice switching AONs for the treatment of neuromuscular disorders such as Duchenne muscular dystrophy (DMD). Many different chemistries of AONs can be used for splice switching modulation, and some of them have now reached regulatory approval. However, despite advances in AON chemistry and design, systemic use of AONs is limited due to poor tissue uptake and sufficient therapeutic efficacy is difficult to achieve. Therefore, there is still a critical need to develop efficient AONs able to target all relevant tissues and international efforts are currently on going to advance new compounds or alternative chemistries with higher therapeutic potential. Here we describe the methods to evaluate the potency of tricyclo-DNA (tcDNA)-AONs, a novel class of AONs which displays unique pharmacological properties and unprecedented uptake in many tissues after systemic administration (Goyenvalle et al., Nat Med 21:270-275, 2015; Goyenvalle et al., J Neuromuscul Dis 3:157-167, 2016; Relizani et al., Mol Ther Nucleic Acids 8:144-157, 2017; Robin et al., Mol Ther Nucleic Acids 7:81-89, 2017). We will focus on the preclinical evaluation of these tcDNA for DMD, specifically targeting the exon 51 of the human dystrophin gene. We will first detail methods to analyze their efficacy both in vitro in human myoblasts and in vivo in the hDMD and mdx52 mouse models and then describe means to evaluate their potential renal toxicity.
37 schema:editor Nec8f7e8228d548c7b6b06ebc6c9e19df
38 schema:genre chapter
39 schema:inLanguage en
40 schema:isAccessibleForFree false
41 schema:isPartOf N751bd34059b44b489d7487dc55b502f1
42 schema:name Use of Tricyclo-DNA Antisense Oligonucleotides for Exon Skipping
43 schema:pagination 381-394
44 schema:productId N3c4f69f4f34a4e1ba29fe7b8015ac949
45 N90bcc42e86d5466e9be47fe912496225
46 Na3639de3ca8a4288bfa741ab060d1542
47 Nee62155853404097a8421f079d7ab9ba
48 schema:publisher Na825b802e46a457790e58b3067c266fd
49 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106471691
50 https://doi.org/10.1007/978-1-4939-8651-4_24
51 schema:sdDatePublished 2019-04-16T09:14
52 schema:sdLicense https://scigraph.springernature.com/explorer/license/
53 schema:sdPublisher N7f14e5251029442397d6a0a120e87f45
54 schema:url https://link.springer.com/10.1007%2F978-1-4939-8651-4_24
55 sgo:license sg:explorer/license/
56 sgo:sdDataset chapters
57 rdf:type schema:Chapter
58 N0f365b4fa29242a692d4f6cde6726eaf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
59 schema:name Transfection
60 rdf:type schema:DefinedTerm
61 N1e82d14b499f4d939188e64d228f4cdd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
62 schema:name Animals
63 rdf:type schema:DefinedTerm
64 N3517131640584aebae84727ee80f56a2 schema:familyName Maruyama
65 schema:givenName Rika
66 rdf:type schema:Person
67 N3c4f69f4f34a4e1ba29fe7b8015ac949 schema:name pubmed_id
68 schema:value 30171555
69 rdf:type schema:PropertyValue
70 N4768b22eabc0470b914dcec3487b1491 rdf:first sg:person.01026571624.29
71 rdf:rest Nde52c78e72dc419c9183c4a36723aacf
72 N626c9a2c092c40f3951c9eb72f52fed8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Liver
74 rdf:type schema:DefinedTerm
75 N68194a9edeff4940858ebb0d286599bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Exons
77 rdf:type schema:DefinedTerm
78 N6c6438a5ac124a828b5cc7b679f000ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Gene Targeting
80 rdf:type schema:DefinedTerm
81 N74d78c908cfc45d18d5ee7eac51b3cc9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Muscular Dystrophy, Duchenne
83 rdf:type schema:DefinedTerm
84 N74fdc178f3e5483a8d088767cf6f27df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Biomarkers
86 rdf:type schema:DefinedTerm
87 N751bd34059b44b489d7487dc55b502f1 schema:isbn 978-1-4939-8650-7
88 978-1-4939-8651-4
89 schema:name Exon Skipping and Inclusion Therapies
90 rdf:type schema:Book
91 N766a599cef2a4b60b3ffa21a74b2bcf6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Cells, Cultured
93 rdf:type schema:DefinedTerm
94 N7f14e5251029442397d6a0a120e87f45 schema:name Springer Nature - SN SciGraph project
95 rdf:type schema:Organization
96 N90bcc42e86d5466e9be47fe912496225 schema:name dimensions_id
97 schema:value pub.1106471691
98 rdf:type schema:PropertyValue
99 Na3639de3ca8a4288bfa741ab060d1542 schema:name doi
100 schema:value 10.1007/978-1-4939-8651-4_24
101 rdf:type schema:PropertyValue
102 Na3e19250e721494eabbba247b3dac7ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Kidney
104 rdf:type schema:DefinedTerm
105 Na825b802e46a457790e58b3067c266fd schema:location New York, NY
106 schema:name Springer New York
107 rdf:type schema:Organisation
108 Nacd67dd374c443d89a459a19777e0584 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name RNA Splicing
110 rdf:type schema:DefinedTerm
111 Naeecbf79d898490db9f1e1b70066736c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Mice
113 rdf:type schema:DefinedTerm
114 Nb0875e27a77d475f899f1f3c7ac6cbae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Myoblasts
116 rdf:type schema:DefinedTerm
117 Nbcad80f6cb7541429579ec72d190d451 rdf:first N3517131640584aebae84727ee80f56a2
118 rdf:rest rdf:nil
119 Nbcd3aae98702418da9c43cfe80395b7a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Humans
121 rdf:type schema:DefinedTerm
122 Nd88676cd27f14e6eafc9cbb8f0eb8e1f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Dystrophin
124 rdf:type schema:DefinedTerm
125 Ndd1a6a0b4a224b538893e9093d19fd6e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Oligodeoxyribonucleotides, Antisense
127 rdf:type schema:DefinedTerm
128 Nde52c78e72dc419c9183c4a36723aacf rdf:first sg:person.01200571036.55
129 rdf:rest rdf:nil
130 Nec8f7e8228d548c7b6b06ebc6c9e19df rdf:first Nf66c4679cc404355b0cc4b412c0ce2f4
131 rdf:rest Nbcad80f6cb7541429579ec72d190d451
132 Nee62155853404097a8421f079d7ab9ba schema:name readcube_id
133 schema:value bc47a79cde86a71777469b21829288ea7894938edce0caec2c7f0d8254b01c21
134 rdf:type schema:PropertyValue
135 Nf66c4679cc404355b0cc4b412c0ce2f4 schema:familyName Yokota
136 schema:givenName Toshifumi
137 rdf:type schema:Person
138 anzsrc-for:10 schema:inDefinedTermSet anzsrc-for:
139 schema:name Technology
140 rdf:type schema:DefinedTerm
141 anzsrc-for:1004 schema:inDefinedTermSet anzsrc-for:
142 schema:name Medical Biotechnology
143 rdf:type schema:DefinedTerm
144 sg:person.01026571624.29 schema:affiliation https://www.grid.ac/institutes/grid.12832.3a
145 schema:familyName Relizani
146 schema:givenName Karima
147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026571624.29
148 rdf:type schema:Person
149 sg:person.01200571036.55 schema:affiliation https://www.grid.ac/institutes/grid.12832.3a
150 schema:familyName Goyenvalle
151 schema:givenName Aurelie
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200571036.55
153 rdf:type schema:Person
154 sg:pub.10.1038/nm.3765 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014266352
155 https://doi.org/10.1038/nm.3765
156 rdf:type schema:CreativeWork
157 sg:pub.10.1186/2044-5040-1-34 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051788803
158 https://doi.org/10.1186/2044-5040-1-34
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1006/bbrc.1997.7328 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026152845
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1016/j.coph.2015.07.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002005310
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1016/j.omtn.2017.02.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084100080
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1016/j.omtn.2017.06.013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1086143160
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1016/j.ymthe.2004.05.031 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045117278
169 rdf:type schema:CreativeWork
170 https://doi.org/10.1016/s1474-4422(16)30035-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049531945
171 rdf:type schema:CreativeWork
172 https://doi.org/10.1038/mt.2016.188 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024312237
173 rdf:type schema:CreativeWork
174 https://doi.org/10.1038/mtna.2014.6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031003220
175 rdf:type schema:CreativeWork
176 https://doi.org/10.1089/nat.2016.0657 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021448721
177 rdf:type schema:CreativeWork
178 https://doi.org/10.1093/nar/29.9.e45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030834024
179 rdf:type schema:CreativeWork
180 https://doi.org/10.1093/nar/gkp841 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005271115
181 rdf:type schema:CreativeWork
182 https://doi.org/10.15252/emmm.201607199 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084343659
183 rdf:type schema:CreativeWork
184 https://doi.org/10.3233/jnd-160146 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013977294
185 rdf:type schema:CreativeWork
186 https://www.grid.ac/institutes/grid.12832.3a schema:alternateName Versailles Saint-Quentin-en-Yvelines University
187 schema:name SQY Therapeutics, UFR des Sciences de la Santé, Montigny-le-Bretonneux, France
188 Université de Versailles St-Quentin, U1179 INSERM, UFR des Sciences de la Santé—LIA BAHN CSM, Versailles, France
189 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...